Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

491 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.
Tuñón J, Steg PG, Bhatt DL, Bittner VA, Díaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Mueller C, Parkhomenko A, Pordy R, Sritara P, Szarek M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Tuñón J, et al. Among authors: goodman sg. Eur Heart J. 2020 Nov 7;41(42):4114-4123. doi: 10.1093/eurheartj/ehaa498. Eur Heart J. 2020. PMID: 32820320 Free PMC article. Clinical Trial.
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial.
Mahaffey KW, Cohen M, Garg J, Antman E, Kleiman NS, Goodman SG, Berdan LG, Reist CJ, Langer A, White HD, Aylward PE, Col JJ, Ferguson JJ 3rd, Califf RM; SYNERGY Trial Investigators. Mahaffey KW, et al. Among authors: goodman sg. JAMA. 2005 Nov 23;294(20):2594-600. doi: 10.1001/jama.294.20.2594. JAMA. 2005. PMID: 16304073 Clinical Trial.
Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial.
Fitchett DH, Langer A, Armstrong PW, Tan M, Mendelsohn A, Goodman SG; INTERACT Trial Long-Term Follow-Up Investigators. Fitchett DH, et al. Among authors: goodman sg. Am Heart J. 2006 Feb;151(2):373-9. doi: 10.1016/j.ahj.2005.05.003. Am Heart J. 2006. PMID: 16442903 Clinical Trial.
491 results